Saxagliptin upregulates nesfatin-1 secretion and ameliorates insulin resistance and metabolic profiles in type 2 diabetes mellitus

Metabolic Syndrome and Related Disorders

Volumn 16, Issue 7, 2018, Pages 336-341

  Chen, Kuanlin ^a   Zhuo, Tiejun ^b   Wang, Jian ^c   Mei, Qing ^d  

^a Jiangshu Jiankang Vocational College   (China)

^b Jiangsu Province Geriatric Hospital   (China)

^c Honghua Health Center   (China)

^d Qinhong Health Center   (China)

Author keywords

HOMA IR; HOMA funciton; nesfatin 1; saxagliptin; type 2 diabetes mellitus

Indexed keywords

ACARBOSE; C PEPTIDE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; NESFATIN 1; PROTEIN DERIVATIVE; SAXAGLIPTIN; UNCLASSIFIED DRUG; ADAMANTANE; CALCIUM BINDING PROTEIN; DIPEPTIDE; DNA BINDING PROTEIN; GLYCOSYLATED HEMOGLOBIN; INSULIN; NERVE PROTEIN; NUCLEOBINDIN;

ADULT; ARTICLE; BLOOD PRESSURE; BODY MASS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; HOMEOSTASIS MODEL ASSESSMENT; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN SECRETION; SYSTOLIC BLOOD PRESSURE; UPREGULATION; AGED; ANALOGS AND DERIVATIVES; BLOOD; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; FOLLOW UP; GLUCOSE BLOOD LEVEL; METABOLOME; MIDDLE AGED;

ACARBOSE; ADAMANTANE; AGED; BLOOD GLUCOSE; CALCIUM-BINDING PROTEINS; DIABETES MELLITUS, TYPE 2; DIPEPTIDES; DNA-BINDING PROTEINS; FEMALE; FOLLOW-UP STUDIES; GLYCATED HEMOGLOBIN A; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; METABOLOME; METFORMIN; MIDDLE AGED; NERVE TISSUE PROTEINS; UP-REGULATION;

EID: 85052938526     PISSN: 15404196     EISSN: 15578518     Source Type: Journal    
DOI: 10.1089/met.2018.0010     Document Type: Article

References (40)

1. Krentz AJ, Patel MB, Bailey CJ. New drugs for type 2 diabetes mellitus: What is their place in therapy? Drugs 2008;68:2131-2162.
2. Fehmann HC, Hering BJ, Wolf MJ, et al. The effects of glucagon-like peptide-I (GLP-I) on hormone secretion from isolated human pancreatic islets. Pancreas 1995;11:196-200.
3. Larsson H, Holst JJ, Ahrén B. Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans. Acta Physiol Scand 1997; 160:413-422.
4. Jadzinsky M, Pfützner A, Paz-Pacheco E, et al. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: A randomized controlled trial. Diabetes Obes Metab 2009;11:611-622.
5. Chacra AR, Tan GH, Apanovitch A, et al. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: A randomised controlled trial. Int J Clin Pract 2009;63:1395-1406.
6. Wang MM, Lin S, Chen YM, et al. Saxagliptin is similar in glycaemic variability more effective in metabolic control than acarbose in aged type 2 diabetes inadequately controlled with metformin. Diabetes Res Clin Pract 2015;108:e67-e70.
7. Barnett AH, Charbonnel B, Li J, et al. Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy. Clin Drug Investig 2013;33:707-717.
8. Oh-I S, Shimizu H, Satoh T, et al. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature 2006; 443:709-712.
9. Kohno D, Nakata M, Maejima Y, et al. Nesfatin-1 neurons in paraventricular and supraoptic nuclei of the rat hypothalamus coexpress oxytocin and vasopressin and are activated by refeeding. Endocrinology 2008;149:1295-1301.
10. Li QC, Wang HY, Chen X, et al. Fasting plasma levels of nesfatin-1 in patients with type 1 and type 2 diabetes mellitus and the nutrient-related fluctuation of nesfatin-1 level in normal humans. Regul Pept 2010;159:72-77.
11. Zhang Z, Li L, Yang M, et al. Increased plasma levels of nesfatin-1 in patients with newly diagnosed type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2012;120: 91-95.
12. American Diabetes Association. Executive summary: Standards of medical care in diabetes-2011. Diabetes Care 2011;34 (Suppl. 1):s4-s10.
13. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modelling. Diabetes Care 2004;27:1487-1495.
14. von Hurst PR, Stonehouse W, Coad J. Vitamin D supplementation reduces insulin resistance in South Asian women living in New Zealand who are insulin resistant and vitamin D deficient-a randomised, placebo-controlled trial. Br J Nutr 2010;103:549-555.
15. Ahrén B, Landin-Olsson M, Jansson PA, et al. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004;89:2078-2084.
16. Gautier JF, Choukem SP, Girard J. Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes. Diabetes Metab 2008;34 (Suppl 2):S65-S72.
17. Farilla L, Bulotta A, Hirshberg B, et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 2003;144: 5149-5158.
18. Nauck MA, Niedereichholz U, Ettler R, et al. Glucagonlike peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 1997;273:E981-E988.
19. D'Alessio DA, Kahn SE, Leusner CR, et al. Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin Invest 1994;93:2263-2266.
20. Ahrén B, Pacini G, Tura A, et al. Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes. Horm Metab Res 2007;39:826-829.
21. Barnett A, Allsworth J, Jameson K, et al. A review of the effects of antihyperglycaemic agents on body weight: The potential of incretin targeted therapies. Curr Med Res Opin 2007;23:1493-1507.
22. Matikainen N, Mänttäri S, Schweizer A, et al. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 2006;49:2049-2057.
23. Noda Y, Miyoshi T, Oe H, et al. Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in non-diabetic subjects: A preliminary report. Cardiovasc Diabetol 2013;12:8.
24. Wang XF, Liu JJ, Xia J, et al. Endogenous glucagon-like peptide-1 suppresses high-fat food intake by reducing synaptic drive onto mesolimbic dopamine neurons. Cell Rep 2015;12:726-733.
25. Stengel A, Goebel M, Yakubov I, et al. Identification and characterization of nesfatin-1 immunoreactivity in endocrine cell types of the rat gastric oxyntic mucosa. Endocrinology 2009;150:232-238.
26. Gonzalez R, Perry RL, Gao X, et al. Nutrient responsive nesfatin-1 regulates energy balance and induces glucosestimulated insulin secretion in rats. Endocrinology 2011; 152:3628-3637.
27. Nakata M, Manaka K, Yamamoto S, et al. Nesfatin-1 enhances glucose-induced insulin secretion by promoting Ca2+ influx through L-type channels in mouse islet b-cells. Endocr J 2011;58:305-313.
28. Drucker DJ, Philippe J, Mojsov S, et al. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci USA 1987;84:3434-3438.
29. Gotoh K, Masaki T, Chiba S, et al. Nesfatin-1, corticotropinreleasing hormone, thyrotropin-releasing hormone, neuronal histamine interact in the hypothalamus to regulate feeding behavior. J Neurochem 2013;124:90-99.
30. Dong J, Xu H, Xu H, et al. Nesfatin-1 stimulates fatty-acid oxidation by activating AMP-activated protein kinase in STZinduced type 2 diabetic mice. PLoS One 2013;8:e83397.
31. Darambazar G, Nakata M, Okada T, et al. Paraventricular NUCB2/nesfatin-1 is directly targeted by leptin and mediates its anorexigenic effect. Biochem Biophys Res Commun 2015;456:913-918.
32. Ramesh N, Mortazavi S, Unniappan S. Nesfatin-1 stimulates glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide secretion from STC-1 cells in vitro. Biochem Biophys Res Commun 2015;462:124-130.
33. AbaciA, Catli G, Anik A, et al. The relation of serum nesfatin-1 level with metabolic and clinical parameters in obese and healthy children. Pediatr Diabetes 2013;14:189-195.
34. Riva M, Nitert MD, Voss U, et al. Nesfatin-1 stimulates glucagon and insulin secretion and beta cell NUCB2 is reduced in human type 2 diabetic subjects. Cell Tissue Res 2011;346:393-405.
35. Ayada C, Turgut G, Turgut S, et al. The effect of chronic peripheral nesfatin-1 application on blood pressure in normal and chronic restraint stressed rats: Related with circulating level of blood pressure regulators. Gen Physiol Biophys 2015; 34:81-88.
36. Zhao Y, Ma X, Wang Q, et al. Nesfatin-1 correlates with hypertension in overweight or obese Han Chinese population. Clin Exp Hypertens 2015;37:51-56.
37. Mason RP, Jacob RF, Kubant R, et al. Dipeptidyl peptidase-4 inhibition with saxagliptin enhanced nitric oxide release and reduced blood pressure and sICAM-1 levels in hypertensive rats. J Cardiovasc Pharmacol 2012;60:467-473.
38. Mason RP, Jacob RF, Kubant R, et al. Effect of enhanced glycemic control with saxagliptin on endothelial nitric oxide release and CD40 levels in obese rats. J Atheroscler Thromb 2011;18:774-783.
39. Shah Z, Pineda C, Kampfrath T, et al. Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways. Vascul Pharmacol 2011;55:2-9.
40. Sokos GG, Nikolaidis LA, Mankad S, et al. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 2006;12:694-699.